Removal of vancomycin in sustained low-efficiency dialysis (SLED): A need for better surveillance and dosing

Ladan Golestaneh, A. Gofran, Michele H. Mokrzycki, Julie L. Chen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aims: This study was de signed to evaluate the extent of vancomycin removal from the blood compartment during sustained low-efficiency dialysis (SLED) and the efficacy of our current vancomycin dosing practice. Material: 10 ICU patients were selected. They all had oliguric renal failure requiring SLED and were on vancomycin therapy. SLED was provided with the Fresenius 2000K machine and used an AV400 polysulfone dialyzer (sieving coefficient for vitamin B12 = 1, and sur face area = 0.7 m2). Method: SLED prescriptions were individualized for each patient but the duration for all was at least 8 hours. The blood flow rate (Qb) and dialysate flow rate (Qd) did not vary between patients by greater than 100 cc per minute. Blood samples were drawn at 0, 2, 4, and 8 hours to determine the extent of reduction in vancomycin level. Results: The total reduction of vancomycin was about 36% with an 8-hour treat ment, when following a typical SLED prescription. Serum vancomycin levels dropped below the therapeutic window (< 15 mcg/ml) at the end of an 8-hour SLED session in almost half of the patients. Drug removal was great est dur ing the first 4 hours (29.5 ± 6.5%) compared to the last 4 hours (9.1 ± 7.4%) of SLED. Conclusions: Vancomycin removal during a typical 8-hour SLED treatment approaches 36%. SLED patients are at risk for undertreatment of their infections. A redosing strategy should be considered if the estimated or measured predialysis level is 20 - 30 mcg/ml. Vancomycin should be redosed with at least 500 mg in most patients at the completion of the SLED. Therapeutic drug monitoring (TDM) is an essential part of any dosing scheme, until further studies are done.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalClinical Nephrology
Volume72
Issue number4
StatePublished - 2009

Fingerprint

Vancomycin
Dialysis
Prescriptions
Drug Monitoring
Dialysis Solutions
Vitamin B 12
Renal Insufficiency
Therapeutics

Keywords

  • Renal replacement therapy
  • SLED
  • Therapeutic drug monitoring
  • Vancomycin

ASJC Scopus subject areas

  • Nephrology

Cite this

Removal of vancomycin in sustained low-efficiency dialysis (SLED) : A need for better surveillance and dosing. / Golestaneh, Ladan; Gofran, A.; Mokrzycki, Michele H.; Chen, Julie L.

In: Clinical Nephrology, Vol. 72, No. 4, 2009, p. 286-291.

Research output: Contribution to journalArticle

@article{785b43914c1e42468a5f3468e69574f5,
title = "Removal of vancomycin in sustained low-efficiency dialysis (SLED): A need for better surveillance and dosing",
abstract = "Aims: This study was de signed to evaluate the extent of vancomycin removal from the blood compartment during sustained low-efficiency dialysis (SLED) and the efficacy of our current vancomycin dosing practice. Material: 10 ICU patients were selected. They all had oliguric renal failure requiring SLED and were on vancomycin therapy. SLED was provided with the Fresenius 2000K machine and used an AV400 polysulfone dialyzer (sieving coefficient for vitamin B12 = 1, and sur face area = 0.7 m2). Method: SLED prescriptions were individualized for each patient but the duration for all was at least 8 hours. The blood flow rate (Qb) and dialysate flow rate (Qd) did not vary between patients by greater than 100 cc per minute. Blood samples were drawn at 0, 2, 4, and 8 hours to determine the extent of reduction in vancomycin level. Results: The total reduction of vancomycin was about 36{\%} with an 8-hour treat ment, when following a typical SLED prescription. Serum vancomycin levels dropped below the therapeutic window (< 15 mcg/ml) at the end of an 8-hour SLED session in almost half of the patients. Drug removal was great est dur ing the first 4 hours (29.5 ± 6.5{\%}) compared to the last 4 hours (9.1 ± 7.4{\%}) of SLED. Conclusions: Vancomycin removal during a typical 8-hour SLED treatment approaches 36{\%}. SLED patients are at risk for undertreatment of their infections. A redosing strategy should be considered if the estimated or measured predialysis level is 20 - 30 mcg/ml. Vancomycin should be redosed with at least 500 mg in most patients at the completion of the SLED. Therapeutic drug monitoring (TDM) is an essential part of any dosing scheme, until further studies are done.",
keywords = "Renal replacement therapy, SLED, Therapeutic drug monitoring, Vancomycin",
author = "Ladan Golestaneh and A. Gofran and Mokrzycki, {Michele H.} and Chen, {Julie L.}",
year = "2009",
language = "English (US)",
volume = "72",
pages = "286--291",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "4",

}

TY - JOUR

T1 - Removal of vancomycin in sustained low-efficiency dialysis (SLED)

T2 - A need for better surveillance and dosing

AU - Golestaneh, Ladan

AU - Gofran, A.

AU - Mokrzycki, Michele H.

AU - Chen, Julie L.

PY - 2009

Y1 - 2009

N2 - Aims: This study was de signed to evaluate the extent of vancomycin removal from the blood compartment during sustained low-efficiency dialysis (SLED) and the efficacy of our current vancomycin dosing practice. Material: 10 ICU patients were selected. They all had oliguric renal failure requiring SLED and were on vancomycin therapy. SLED was provided with the Fresenius 2000K machine and used an AV400 polysulfone dialyzer (sieving coefficient for vitamin B12 = 1, and sur face area = 0.7 m2). Method: SLED prescriptions were individualized for each patient but the duration for all was at least 8 hours. The blood flow rate (Qb) and dialysate flow rate (Qd) did not vary between patients by greater than 100 cc per minute. Blood samples were drawn at 0, 2, 4, and 8 hours to determine the extent of reduction in vancomycin level. Results: The total reduction of vancomycin was about 36% with an 8-hour treat ment, when following a typical SLED prescription. Serum vancomycin levels dropped below the therapeutic window (< 15 mcg/ml) at the end of an 8-hour SLED session in almost half of the patients. Drug removal was great est dur ing the first 4 hours (29.5 ± 6.5%) compared to the last 4 hours (9.1 ± 7.4%) of SLED. Conclusions: Vancomycin removal during a typical 8-hour SLED treatment approaches 36%. SLED patients are at risk for undertreatment of their infections. A redosing strategy should be considered if the estimated or measured predialysis level is 20 - 30 mcg/ml. Vancomycin should be redosed with at least 500 mg in most patients at the completion of the SLED. Therapeutic drug monitoring (TDM) is an essential part of any dosing scheme, until further studies are done.

AB - Aims: This study was de signed to evaluate the extent of vancomycin removal from the blood compartment during sustained low-efficiency dialysis (SLED) and the efficacy of our current vancomycin dosing practice. Material: 10 ICU patients were selected. They all had oliguric renal failure requiring SLED and were on vancomycin therapy. SLED was provided with the Fresenius 2000K machine and used an AV400 polysulfone dialyzer (sieving coefficient for vitamin B12 = 1, and sur face area = 0.7 m2). Method: SLED prescriptions were individualized for each patient but the duration for all was at least 8 hours. The blood flow rate (Qb) and dialysate flow rate (Qd) did not vary between patients by greater than 100 cc per minute. Blood samples were drawn at 0, 2, 4, and 8 hours to determine the extent of reduction in vancomycin level. Results: The total reduction of vancomycin was about 36% with an 8-hour treat ment, when following a typical SLED prescription. Serum vancomycin levels dropped below the therapeutic window (< 15 mcg/ml) at the end of an 8-hour SLED session in almost half of the patients. Drug removal was great est dur ing the first 4 hours (29.5 ± 6.5%) compared to the last 4 hours (9.1 ± 7.4%) of SLED. Conclusions: Vancomycin removal during a typical 8-hour SLED treatment approaches 36%. SLED patients are at risk for undertreatment of their infections. A redosing strategy should be considered if the estimated or measured predialysis level is 20 - 30 mcg/ml. Vancomycin should be redosed with at least 500 mg in most patients at the completion of the SLED. Therapeutic drug monitoring (TDM) is an essential part of any dosing scheme, until further studies are done.

KW - Renal replacement therapy

KW - SLED

KW - Therapeutic drug monitoring

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=70350367198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350367198&partnerID=8YFLogxK

M3 - Article

C2 - 19825334

AN - SCOPUS:70350367198

VL - 72

SP - 286

EP - 291

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 4

ER -